0000950170-23-051187.txt : 20231002 0000950170-23-051187.hdr.sgml : 20231002 20231002171720 ACCESSION NUMBER: 0000950170-23-051187 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 12 CONFORMED PERIOD OF REPORT: 20230929 ITEM INFORMATION: Cost Associated with Exit or Disposal Activities ITEM INFORMATION: Material Impairments ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers FILED AS OF DATE: 20231002 DATE AS OF CHANGE: 20231002 FILER: COMPANY DATA: COMPANY CONFORMED NAME: SQZ Biotechnologies Co CENTRAL INDEX KEY: 0001604477 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 462431115 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-39662 FILM NUMBER: 231300700 BUSINESS ADDRESS: STREET 1: 200 ARSENAL YARDS BLVD., STE. 210 CITY: WATERTOWN STATE: MA ZIP: 02472 BUSINESS PHONE: 617-898-8824 MAIL ADDRESS: STREET 1: 200 ARSENAL YARDS BLVD., STE. 210 CITY: WATERTOWN STATE: MA ZIP: 02472 8-K 1 sqzb-20230929.htm 8-K 8-K
0001604477false00016044772023-09-292023-09-29

 

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): September 29, 2023

 

 

SQZ BIOTECHNOLOGIES COMPANY

(Exact name of Registrant as Specified in Its Charter)

 

 

Delaware

001-39662

46-2431115

(State or Other Jurisdiction
of Incorporation)

(Commission File Number)

(IRS Employer
Identification No.)

 

 

 

 

 

200 Arsenal Yards Blvd

Suite 210

 

Watertown, Massachusetts

 

02472

(Address of Principal Executive Offices)

 

(Zip Code)

 

Registrant’s Telephone Number, Including Area Code: 617 758-8672

 

N/A

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

 

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:


Title of each class

 

Trading
Symbol(s)

 


Name of each exchange on which registered

Common Stock, $0.001 par value per share

 

SQZB

 

OTC Markets

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 

Item 2.05 Costs Associated with Exit or Disposal Activities.

On September 29, 2023, the Board of Directors (the “Board”) of SQZ Biotechnologies Company (the “Company”) approved a reduction in the Company’s workforce by approximately eighty percent (the “Workforce Reduction”). The decision was based on cost-reduction initiatives intended to reduce the Company’s ongoing operating expenses while it pursues strategic alternatives. The Company expects to continue to treat currently enrolled patients in its enhanced antigen presenting cell (eAPC) and activating antigen carriers (AAC) programs in HPV16+ tumors.


The Company currently estimates that it will incur approximately $1.5 million in charges in connection with the Workforce Reduction, primarily consisting of employee-related benefits and related costs including continuation of group health insurance coverage for a specified period to the affected employees, approximately $100,000 of which is anticipated to result in cash expenditures. The Company expects that the majority of these charges will be incurred in the third quarter of 2023. The charges the Company expects to incur are subject to assumptions, and actual charges may differ from the amount disclosed in this Current Report on Form 8-K.

Item 2.06 Material Impairments.

The information contained in Item 2.05 above is incorporated herein by reference. Due to the Workforce Reduction and resulting reduced space requirements, the Company currently estimates that it will recognize a non-cash impairment charge of approximately $22 million related to its facility lease right of use asset and certain equipment. The Company does not expect material cash expenditures in connection with the impairment charge. The charges the Company expects to incur are subject to assumptions, and actual charges may differ from the amount disclosed in this Current Report on Form 8-K.

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

In connection with the Workforce Reduction, on October 3, 2023, the Company and each of Howard Bernstein, Ph.D., Interim Chief Executive Officer of the Company, Richard Capasso, Chief Accounting Officer of the Company, Marshelle Smith Warren, M.D., Chief Medical Officer of the Company, and Lawrence Knopf, General Counsel of the Company (collectively, the “Executive Officers”) entered into a transition agreement amending the terms of the Executive Officer’s employment agreement with the Company. The transition agreements provide for an agreed employment termination date for the Executive Officers of November 15, 2023, subject to certain early termination events, and a reduction in the current annual base salaries and expected working time commitments of the Executive Officers effective October 3, 2023, as follows: 50% for Dr. Bernstein, 25% for Mr. Capasso, 75% for Dr. Warren and 50% for Mr. Knopf.

Following their respective employment termination dates, the Executive Officers are expected to enter into consulting agreements with the Company under which they will perform consulting services on an as-needed basis for an hourly consulting fee of $350 for Dr. Bernstein, $250 for Mr. Capasso; $275 for Dr. Warren and $300 for Mr. Knopf.

Under each Executive Officer’s transition agreement, if the Executive Officer remains employed through the first of the Executive Officer’s agreed employment termination date, the date of a change in control (within the meaning of the Executive Officer’s employment agreement) of the Company, immediately prior to the commencement of a voluntary or involuntary insolvency proceeding of the Company under the U.S. Bankruptcy Code (or similar law) or the Company’s earlier termination of the Executive Officer’s employment other than for cause (within the meaning of the Executive Officer’s employment agreement), then, , the Executive Officer will be released from an obligation, in certain circumstances, to repay the retention recognition bonus awarded on July 10, 2023 and, if a change in control occurs prior to the Executive Officer’s employment termination date or within the 3-month period thereafter and subject to the Executive Officer signing on or before the 45th day following the Separation Date, and not revoking, a general release of claims and the Executive Officer’s continued compliance with the Executive’s Officer’s restrictive covenant obligations to the Company, the Executive Officer will be entitled to a payment equal to 25% of the Executive Officer’s average annual base salary in effect immediately prior to October 3, 2023 plus 25% of the Executive Officer’s target annual bonus amount in effect immediately prior to October 3, 2023. The foregoing termination rights supersede in their entirety the severance payments and benefits provisions of the Company’s employment agreements with the Executive Officers.

Forward-Looking Statements

This Current Report on Form 8-K contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this Current Report on Form 8-K that do not relate to matters of historical fact should be considered forward-looking statements, including without limitation statements relating to the anticipated charges associated with the Workforce Reduction, anticipated non-cash impairment charges in connection with reduced space requirements, the Company’s plans regarding the employment and subsequent consultancy of the Company’s Executive Officers, the Company’s plans to pursue strategic

 

 

alternatives, the Company’s plans to continue to treat patients and the expected financial and operational impacts of the Company’s cost-reduction initiatives. These forward-looking statements are based on management's current expectations. Actual results could differ from those projected in any forward-looking statements due to several risk factors, including but not limited to the important factors discussed under the caption "Risk Factors" in the Company’s Quarterly Reports on Form 10-Q, Annual Reports on Form 10-K, and other filings with the U.S. Securities and Exchange Commission could cause actual results to differ materially from those indicated by the forward-looking statements. Any forward-looking statements represent management's estimates as of the date of this Current Report on Form 8-K and the Company undertakes no duty to update these forward-looking statements, whether as a result of new information, the occurrence of current events, or otherwise, unless required by law.

 

 

 

 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

 

SQZ BIOTECHNOLOGIES COMPANY

 

 

 

 

Date:

October 2, 2023

By:

/s/ Lawrence Knopf

 

 

 

Lawrence Knopf

General Counsel

 

 

 EX-101.PRE 2 sqzb-20230929_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT EX-101.LAB 3 sqzb-20230929_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Pre-commencement Issuer Tender Offer Entity Address, State or Province Trading Symbol Soliciting Material Entity Address, City or Town Written Communications Entity Central Index Key Entity Tax Identification Number Entity Registrant Name Entity Ex Transition Period Entity Information, Former Legal or Registered Name Document Period End Date Entity Address, Postal Zip Code Entity Incorporation, State or Country Code Local Phone Number City Area Code Pre-commencement Tender Offer Cover [Abstract] Security Exchange Name Entity Emerging Growth Company Amendment Flag Securities Act File Number Entity Address, Address Line Two Entity Address, Address Line One Title of 12(b) Security Document Type EX-101.SCH 4 sqzb-20230929.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 100000 - Document - Document And Entity Information link:presentationLink link:calculationLink link:definitionLink XML 5 R1.htm IDEA: XBRL DOCUMENT v3.23.3
Document And Entity Information
Sep. 29, 2023
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Sep. 29, 2023
Entity Registrant Name SQZ BIOTECHNOLOGIES COMPANY
Entity Central Index Key 0001604477
Entity Emerging Growth Company true
Securities Act File Number 001-39662
Entity Incorporation, State or Country Code DE
Entity Tax Identification Number 46-2431115
Entity Address, Address Line One 200 Arsenal Yards Blvd
Entity Address, Address Line Two Suite 210
Entity Address, City or Town Watertown
Entity Address, State or Province MA
Entity Address, Postal Zip Code 02472
City Area Code 617
Local Phone Number 758-8672
Entity Information, Former Legal or Registered Name N/A
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Entity Ex Transition Period false
Title of 12(b) Security Common Stock, $0.001 par value per share
Trading Symbol SQZB
XML 6 sqzb-20230929_htm.xml IDEA: XBRL DOCUMENT 0001604477 2023-09-29 2023-09-29 0001604477 false 8-K 2023-09-29 SQZ BIOTECHNOLOGIES COMPANY DE 001-39662 46-2431115 200 Arsenal Yards Blvd Suite 210 Watertown MA 02472 617 758-8672 N/A false false false false Common Stock, $0.001 par value per share SQZB true false EXCEL 7 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 8 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 9 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 10 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.3 html 1 24 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document And Entity Information Sheet http://sqzbiotech.com/20230929/taxonomy/role/Role_DocumentDocumentAndEntityInformation Document And Entity Information Cover 1 false false All Reports Book All Reports sqzb-20230929.htm sqzb-20230929.xsd sqzb-20230929_lab.xml sqzb-20230929_pre.xml http://xbrl.sec.gov/dei/2023 true false JSON 12 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "sqzb-20230929.htm": { "nsprefix": "sqzb", "nsuri": "http://sqzbiotech.com/20230929", "dts": { "inline": { "local": [ "sqzb-20230929.htm" ] }, "schema": { "local": [ "sqzb-20230929.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] }, "labelLink": { "local": [ "sqzb-20230929_lab.xml" ] }, "presentationLink": { "local": [ "sqzb-20230929_pre.xml" ] } }, "keyStandard": 24, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2023": 2 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 26, "unitCount": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 24 }, "report": { "R1": { "role": "http://sqzbiotech.com/20230929/taxonomy/role/Role_DocumentDocumentAndEntityInformation", "longName": "100000 - Document - Document And Entity Information", "shortName": "Document And Entity Information", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "C_ab8c4c83-b096-46d8-be27-4c7376614953", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "sqzb-20230929.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_ab8c4c83-b096-46d8-be27-4c7376614953", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "sqzb-20230929.htm", "first": true, "unique": true } } }, "tag": { "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://sqzbiotech.com/20230929/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r3" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://sqzbiotech.com/20230929/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://sqzbiotech.com/20230929/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://sqzbiotech.com/20230929/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://sqzbiotech.com/20230929/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r1" ] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://sqzbiotech.com/20230929/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://sqzbiotech.com/20230929/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://sqzbiotech.com/20230929/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r4" ] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://sqzbiotech.com/20230929/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://sqzbiotech.com/20230929/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r1" ] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://sqzbiotech.com/20230929/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://sqzbiotech.com/20230929/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Securities Act File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://sqzbiotech.com/20230929/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://sqzbiotech.com/20230929/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://sqzbiotech.com/20230929/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r6" ] }, "dei_EntityInformationFormerLegalOrRegisteredName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityInformationFormerLegalOrRegisteredName", "presentation": [ "http://sqzbiotech.com/20230929/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Information, Former Legal or Registered Name", "documentation": "Former Legal or Registered Name of an entity" } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://sqzbiotech.com/20230929/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r1" ] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://sqzbiotech.com/20230929/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityExTransitionPeriod", "presentation": [ "http://sqzbiotech.com/20230929/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Ex Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r7" ] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://sqzbiotech.com/20230929/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://sqzbiotech.com/20230929/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r2" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://sqzbiotech.com/20230929/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r0" ] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://sqzbiotech.com/20230929/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://sqzbiotech.com/20230929/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r1" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://sqzbiotech.com/20230929/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r5" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r7": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" } } } ZIP 13 0000950170-23-051187-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0000950170-23-051187-xbrl.zip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end